Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909090 · ClinicalTrials.gov registry record · NA
Macular Pigment and Glare Disability
A NA study, sponsored by University of Georgia.
- Completed
- Registry status
- NA
- Development phase
- 109
- Enrollment target
NCT00909090 is a NA study that has completed, run by University of Georgia. The registered enrollment target is 109 participants.
The verdict
NCT00909090, a NA study, has completed, sponsored by University of Georgia.
- COMPLETED
- Registry status
- NA
- Development phase
- 109 participants
- Enrollment target
Study Summary
The purpose of this study is: I. To measure MP optical density (MPOD) in two groups (experimental and placebo) of 50 subjects each (N = 100), during an Lutein + Zeaxanthin supplementation period of 12 months. II. To test the hypothesis that increases in MP (via 12 mg daily Lutein + Zeaxanthin supplementation) will result in significantly improved visual performance under disability glare conditions. III. To test the hypothesis that increases in MP (via 12 mg daily L + Z supplementation) will result in significantly reduced photostress recovery times. IV. To test the hypothesis that increases in MP (via 12 mg daily L + Z supplementation) will result in improved contrast enhancement.
Interventions
- DIETARY_SUPPLEMENT 12 mg Lutein + Zeaxanthin
- DIETARY_SUPPLEMENT Visually identical placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00909090
The ClinicalTrials.gov registry entry for NCT00909090 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Georgia, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 12 mg Lutein + Zeaxanthin is the first listed.
NCT00909090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00909090 about?
NCT00909090 is a clinical study titled "Macular Pigment and Glare Disability". The purpose of this study is: I. To measure MP optical density (MPOD) in two groups (experimental and placebo) of 50 subjects each (N = 100), during an Lutein + Zeaxanthin supplementation period of 12 months. II. To test the hypothesis that increases in MP (via 12 mg daily Lutein + Zeaxanthin supp...
What is the current status of trial NCT00909090?
This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2009-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00909090?
The interventions under investigation include: 12 mg Lutein + Zeaxanthin (DIETARY_SUPPLEMENT), Visually identical placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00909090?
This trial is sponsored by University of Georgia, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.